249 related articles for article (PubMed ID: 11848524)
1. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.
Sourla A; Lembessis P; Mitsiades C; Dimopoulos T; Skouteris M; Metsinis M; Ntounis A; Ioannidis A; Katsoulis A; Kyragiannis V; Lambou T; Tsintavis A; Koutsilieris M
Anticancer Res; 2001; 21(5):3565-70. PubMed ID: 11848524
[TBL] [Abstract][Full Text] [Related]
2. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
Lembessis P; Msaouel P; Halapas A; Sourla A; Panteleakou Z; Pissimissis N; Milathianakis C; Bogdanos J; Papaioannou A; Maragoudakis E; Dardoufas C; Dimopoulos T; Koutsilieris M
Clin Chem Lab Med; 2007; 45(11):1488-94. PubMed ID: 17924845
[TBL] [Abstract][Full Text] [Related]
3. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Mitsiades CS; Lembessis P; Sourla A; Milathianakis C; Tsintavis A; Koutsilieris M
Clin Exp Metastasis; 2004; 21(6):495-505. PubMed ID: 15679047
[TBL] [Abstract][Full Text] [Related]
4. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Koutsilieris M; Lembessis P; Luu-The V; Sourla A
Clin Exp Metastasis; 1999; 17(10):823-30. PubMed ID: 11089880
[TBL] [Abstract][Full Text] [Related]
5. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
7. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Labrie F; Candas B; Gomez JL; Cusan L
Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
[TBL] [Abstract][Full Text] [Related]
8. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
Okegawa T; Noda H; Kato M; Miyata A; Nutahara K; Higashihara E
Prostate; 2000 Aug; 44(3):210-8. PubMed ID: 10906737
[TBL] [Abstract][Full Text] [Related]
9. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
[TBL] [Abstract][Full Text] [Related]
10. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction.
Ghossein RA; Osman I; Bhattacharya S; Ferrara J; Fazzari M; Cordon-Cardo C; Scher HI
Diagn Mol Pathol; 1999 Jun; 8(2):59-65. PubMed ID: 10475379
[TBL] [Abstract][Full Text] [Related]
11. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
[TBL] [Abstract][Full Text] [Related]
12. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
13. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Xu T; Chen X; Wang XF; Hou SK; Zhu JC; Zhang XD; Huang XB
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):164-8. PubMed ID: 15100735
[TBL] [Abstract][Full Text] [Related]
14. Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Okegawa T; Yoshioka J; Morita R; Nutahara K; Tsukada Y; Higashihara E
Int J Urol; 1998 Jul; 5(4):349-56. PubMed ID: 9712443
[TBL] [Abstract][Full Text] [Related]
15. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
17. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?
Adsan O; Cecchini MG; Bisoffi M; Wetterwald A; Klima I; Danuser HJ; Studer UE; Thalmann GN
BJU Int; 2002 Oct; 90(6):579-85. PubMed ID: 12230621
[TBL] [Abstract][Full Text] [Related]
18. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.
Su SL; Boynton AL; Holmes EH; Elgamal AA; Murphy GP
Semin Surg Oncol; 2000; 18(1):17-28. PubMed ID: 10617893
[TBL] [Abstract][Full Text] [Related]
19. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
20. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
